Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)
|ClinicalTrials.gov Identifier: NCT00625157|
Recruitment Status : Completed
First Posted : February 28, 2008
Last Update Posted : February 29, 2008
Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin.
The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.
|Condition or disease||Intervention/treatment||Phase|
|Discoid Lupus Erythematosus||Drug: ASF 1096 0.5 % cream Drug: ASF 1096 placebo cream||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Patients With Newly Developed Discoid Lupus Erythematosus (DLE) Lesions. An International Multi-Centre Clinical Phase 2, Placebo Controlled and Double Blind Proof of Concept Study (2)|
|Experimental: 1||Drug: ASF 1096 0.5 % cream|
|Placebo Comparator: 2||Drug: ASF 1096 placebo cream|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00625157
|Roskilde Hospital, Denmark|